In poorly immunogenic tumor models, the use of CTLA-4-blocking antibodies alone was not sufficient to improve patient survival/shrink tumor mass, but in combination with a DC vaccine, patients with melanoma had increased TILs, specific T cell responses, and clinical benefit in a pre-clinical trial [175]. This evidence concerns the gene CTLA4 and melanoma.